<DOC>
	<DOCNO>NCT00048945</DOCNO>
	<brief_summary>The purpose study determine safety efficacy Pegasys + placebo + lamivudine versus lamivudine alone patient lamivudine versus lamivudine alone patient hepatitis B antigen CHB .</brief_summary>
	<brief_title>Efficacy Safety Study Pegasys Treatment Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Clinical diagnosis hepatitis B Not pregnant Treatment hepatitis B past 6 month Other hepatitis infection Severe liver disease Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>